1. Introduction {#sec1}
===============

Diet composition importantly influences metabolic responses whose dysregulation leads to obesity, diabetes and cancer [@bib1]. But how exactly different diets modulate underlying biological functions remains unclear. In order to appropriately face the dietary change, the organism needs to regulate metabolic flexibility, which is the capacity to continuously adjust use of energy substrates (primarily glucose and fatty acids) based on energy supply and demand, and to achieve stability through physiological and behavioral adaptation to the new diet. However, these adaptive responses can lead to pathology if not adequately regulated. Consequently, a high-fat diet (HFD) will not only provide high levels of energy, but will also cause a set of allostatic modifications influencing both energy intake and storage so as to ultimately maintain the newly acquired weight. This is likely one of the reasons why fighting against obesity is a very difficult and challenging task. Thus, understanding the biological mechanisms regulating metabolic flexibility might lead to better therapeutic strategies tackling metabolic disorders.

HFD consumption plays a significant role in the development of insulin and leptin resistance in the central nervous system (CNS) [@bib2]. In addition, recent studies have demonstrated that nutrients are not only a source of calories, but also work as intracellular signals capable of modifying the activity of specific molecular cascades [@bib3; @bib4]. However, little is known about the underlying CNS mechanisms that regulate metabolic flexibility in response to dietary changes.

Endocannabinoid signaling through the cannabinoid type-1 (CB~1~) receptor plays a key role in energy balance regulation [@bib5; @bib6] and, importantly, its physiological functions are influenced by the diet and especially by the consumption of fat [@bib7; @bib8]. Within the rodent hypothalamus, CB~1~ receptor mRNA is highly expressed in the ventromedial nucleus (VMN) [@bib9; @bib10]. This structure has been long associated with the regulation of food intake and body weight [@bib11].

VMN neurons, particularly those expressing the steroidogenic factor 1 (SF1, also named NR5A1; [@bib12; @bib13]) are critically involved in the regulation of energy balance [@bib14] and exert this function by projecting both locally, within the VMN, as well as to other hypothalamic and extra-hypothalamic sites. In particular, recent studies have shown that SF1-positive neurons project to proopiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus (ARC) and to a number of autonomic centers, thus regulating sympathetic nervous system (SNS) outflow [@bib15]. The adipocyte-secreted hormone leptin directly activates SF1-positive neurons in the VMN and this action is required for normal body weight regulation, since deletion of the leptin receptor in SF1 neurons favors diet-induced obesity (DIO) [@bib16]. Additionally, the expression of the phosphatidyl inositol 3-kinase (PI3K, p110alpha), a downstream molecular target of leptin, in SF1-positive neurons is required for the anorectic action of leptin and the appropriate regulation of energy expenditure in response to an HFD [@bib17]. Finally, selective inactivation of the suppressor of cytokine signaling 3 (SOCS3), a negative regulator of leptin signaling, in SF1 neurons facilitates leptin-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) in this neuronal population, leading to enhanced anorectic and weight-reducing effects of exogenous leptin [@bib18].

Intra-VMN administration of the endocannabinoid anandamide stimulates food intake in rats [@bib19] and treatment of hypothalamic slice preparations with a specific CB~1~ receptor agonist inhibits the electrical activity of SF1-positive neurons [@bib20]. However, the physiological relevance of CB~1~ receptors in the VMN in the regulation of metabolic homeostasis remains to be established. Here we used mice carrying a deletion of the *CB*~*1*~ receptor gene in SF1-positive neurons (SF1-*CB*~*1*~-KO) [@bib21] and studied their behavioral and metabolic responses to a normocaloric standard chow and to a 40% HFD, respectively. These studies reveal that CB~1~ receptors in VMN neurons exert a diet-dependent bidirectional role in regulating energy balance and metabolic responses to leptin, thereby representing a molecular switch for correct metabolic flexibility.

2. Material and methods {#sec2}
=======================

2.1. Study approval {#sec2.1}
-------------------

All experiments were conducted in strict compliance with the European Union recommendations (2010/63/EU) and were approved by the French Ministry of Agriculture and Fisheries (animal experimentation authorization n° 3309004) and the local ethical committee of the University of Bordeaux (project authorization n° 5012062A). Maximal efforts were made to reduce the suffering and the number of animals used.

2.2. Animals {#sec2.2}
------------

Conditional mutant mice lacking *CB*~*1*~ receptor gene in SF1-positive cells (*CB*~*1*~^*SF1Cre*;*f/f*^) hereafter called SF1-*CB*~*1*~-KO and their SF1-Cre negative, wild-type littermates (*CB*~*1*~^*f*/*f*^), hereafter called SF1-*CB*~*1*~-WT, were generated, maintained and genotyped as previously described in Ref. [@bib21]. All mice used in the study were male littermates and they were on a C57BL/6N genetic background (at least seven backcrossings). Effective Cre-mediated deletion of *CB*~*1*~ in the VMN was assessed by *in situ* hybridization (see below). 7-week-old male mice were individually housed in a thermo-regulated animal facility (22 C ± 2 °C), with a 12 h/12 h light/dark cycle (light on at 1 a.m., light off at 1 p.m.). Animals had *ad libitum* access to water and a standard rodent diet (Standard Rodent Diet A03, 3.2 kcal/g, SAFE, France) unless otherwise specified. For high-fat diet (HFD) studies, 7-weeks old male mice were placed on an HFD with 40% of calories from fat (40% HFD, Research Diets, 4.54 kcal/g, New Brunswick, NJ). Food intake and body weight were recorded daily. Feed efficiency was calculated as body weight gained over caloric intake × 100. At the end of the study, mice were sacrificed by cervical dislocation or anesthetized to undergo perfusion, and tissues collected for further molecular and biochemical analysis. Number of animals used for each experiment is detailed in the figures legends. Experimenters were always blind to genotypes and, when possible, to the treatments.

2.3. Body composition analysis {#sec2.3}
------------------------------

Assessment of lean and fat mass in 15-weeks old conscious male mice was performed using a nuclear echo magnetic resonance imaging whole-body composition analyzer (Echo MRI 900; EchoMedical Systems, Houston, TX, USA).

2.4. Food intake response to leptin {#sec2.4}
-----------------------------------

Hoppers containing chow were removed from the cages 1 h before the administration of leptin \[depending on studies, 5 mg/kg or 2.5 mg/kg, ip; mouse recombinant leptin obtained from Dr. A.F. Parlow, National Hormone and Pituitary Program (Torrance, CA)\] or its vehicle (phosphate buffer saline, PBS), which occurred 4 h before the onset of the dark phase, when food hoppers were returned to the cages, as in Ref. [@bib22; @bib23]. Food intake was recorded 1, 2 and 24 h afterwards. Body weight was measured immediately before and 24 h after the treatment. The leptin food intake studies were performed using a within subjects design in which mice received both vehicle and leptin in counterbalanced order.

2.5. Glucose tolerance test (GTT) and insulin tolerance test (ITT) {#sec2.5}
------------------------------------------------------------------

For the GTT, 16--17 weeks old male mice underwent an overnight fast and were injected ip with 2 g/kg of [d]{.smallcaps}-Glucose (Sigma Aldrich, St Louis, MO). For the ITT, animals underwent a 6 h fast and were injected ip with 0.5 U/kg of insulin (Humulin, Lilly, France). Blood samples were collected from the tail vein and glucose was measured using glucose sticks (OneTouch, Vita, France).

2.6. Indirect calorimetry {#sec2.6}
-------------------------

Indirect calorimetry, in-cage locomotor activity and gas exchange analysis were carried out in calorimetric chambers (TSE systems, Bad Homburg, Germany) after 72 h of acclimatization, as previously described in Ref. [@bib22]. VO~2~ values reported in figures were expressed per animal. Unless specified, studies were carried out at 22 °C. To evaluate metabolic changes in response to cold (15 °C) or to an acute injection of leptin, recordings were respectively carried out in chow-fed male mice exposed for 24 h to 15 °C starting at the onset of the dark or in male mice maintained at 22 °C and injected with vehicle or leptin (2.5 mg/kg) in the light phase, 4 h before the onset of the dark.

2.7. Positron emission tomography (PET) {#sec2.7}
---------------------------------------

For the studies using the \[^18^F\]- fluorodeoxyglucose (FDG), chow-fed 16-week-old male SF1-*CB*~*1*~-KO and their WT littermates were analyzed in three different sessions. In the first session, mice were placed at 24 °C and then treated ip with a vehicle solution and a reference CT scan with PET images was recorded as in Ref. [@bib24] to properly evaluate subsequent tracer absorption in the BAT. Scans were performed with a PET system (Explore Vista, GE). The second session begun 1 h later. Mice were placed in a cold room (6 °C) for 3 h, then slightly anesthetized with sevoflurane, injected with \[^18^F\]-FDG (15 MBq) and placed back in the cold room for 1 h to evaluate the tracer\'s absorption. Five days later, the experiment was repeated in the same animals treated with the β3-adrenergic receptor agonist CL 316,243 and maintained at 24 °C. \[^18^F\]-FDG accumulation data on PET images are expressed as standard absorption values (SUV), representing the radioactivity per gram of tissue, divided by the radioactivity dose injected per gram of animal.

2.8. Quantitative real time PCR (qPCR) {#sec2.8}
--------------------------------------

qPCR assays on epididymal white adipose tissue (WAT), adrenals, testis, pituitary and hypothalamus (defined caudally by the mammillary bodies, rostrally by the optic chiasm, laterally by the optic tract, and superiorly by the apex of the hypothalamic third ventricle) were performed with a LightCycler^®^ 480 Real-Time PCR System (Roche Diagnostics, Meylan, France). qPCR reactions and analysis were carried out as in Ref. [@bib25]. For qPCR studies done after leptin treatment, chow-fed male mice were sacrificed 30 min after the administration of the hormone (2.5 mg/kg, ip). Primers sequences are reported in [Supplementary Table 1 in the Supplementary Information](#appsec2){ref-type="sec"}. For determination of the reference genes, the GeNorm method was used. Relative expression analysis was corrected for PCR efficiency and normalized against two reference genes. The relative level of expression was calculated using the comparative (2^−ΔΔCT^) method.

2.9. Double fluorescent *in situ* hybridization (FISH) {#sec2.9}
------------------------------------------------------

FISH was performed as previously described in Ref. [@bib21]. Slides were analyzed by epifluorescence microscopy (Leica, Nanterre, France).

2.10. Immunohistochemistry (IHC) {#sec2.10}
--------------------------------

Chow-fed male SF1-*CB*~*1*~-KO and their WT littermates received either leptin (2.5 mg/kg, ip) or its vehicle 4 h before the onset of the dark and 1 h later were anesthetized with 0.1 ml pentobarbital and perfused transcardially with ice-cold PBS and 4% paraformaldehyde (PFA). In a different series of experiments, male SF1-*CB*~*1*~-KO and their WT littermates maintained on 40% HFD for 2 weeks received leptin (5 mg/kg, ip) or its vehicle as described above and 1 h later were anesthetized and perfused transcardially. Brains were collected and maintained in a 4% PFA solution for 24 h at 4 °C and subsequently transferred to a 30% sucrose solution for one week at 4 °C. Brains were then cut with a cryostat (30 μm, CM 1950, Leica) and sections stored at −20 °C in antifreeze solution until further histological processing. Sections were washed in PBS (pH = 7.4) for 1 h before being treated with a solution of 1% NaOH (1 M), 1% H~2~O~2~ in PBS for 20 min, washed in PBS, and then incubated for 10 min in a 0.3% glycine solution. Sections were then placed in a 20% SDS solution for 10 min, washed in PBS, and then incubated in 8% goat serum (Dako, Trappes, France), 0.4% Triton X 100 (Sigma Aldrich, St Louis, MO) solution for 2 h. Sections were incubated overnight at 4 °C in a solution containing rabbit serum phospho-STAT3 tyr 705 (1:500, catalog \# 9131, Cell Signaling technologies, Beverly, MA), 4% goat serum and 0.4% Triton X 100. The following day, sections were washed in a 1% goat serum, 0.02% Triton X 100 solution, then incubated in a 4% goat serum solution containing 1:250 biotinylated goat anti-rabbit secondary antibody for 1 h, then washed in a 1% goat serum solution, followed by 1 h incubation in an avidin-biotin complex solution (Vectastain Elite ABC Kit, Vector laboratories, Burlingame, CA). Sections were incubated in a diaminobenzidine tetrahydrochloride (DAB; Vectastain Peroxidase Substrate Kit, Vector Laboratories) solution. Sections were finally washed, dehydrated and mounted on SuperFrost slides, then visualized at the microscope (DM5000, Leica). All sections containing the VMN were rostro-caudally (from Bregma −1.22 mm to Bregma −1.82 mm) analyzed to examine distribution of phospho-STAT3 staining. The number of phospho-STAT3 positive cells was counted by an observer blind to the genotype or treatment using a grid reticule (520 × 520 μm) under a 20× microscope objective (Leitz Aristoplan, Leitz Wetzlar, Germany).

2.11. Western blot analysis {#sec2.11}
---------------------------

Proteins from epididymal WAT were extracted and quantified and western blots carried out as in Ref. [@bib26]. Membranes were incubated with the following primary antibodies: β3-adrenergic receptor (1:2000, catalog \# 15688, Millipore, Molsheim, France), adipose triglyceride lipase (ATGL, 1:1000, catalog \# 2439, Cell Signaling), hormone-sensitive lipase (HSL, 1:1000, catalog \# 4107, Cell Signaling), phospho-HSL ser 563 (1:1000, catalog \# 4139, Cell Signaling), phospho-HSL ser 660 (1:1000, catalog \# 4126, Cell Signaling) and β-actin (1:4000, catalog \# 4967, Cell Signaling). β-actin was used as loading control. Immunoreactive bands were visualized using enhanced chemiluminescence (ECL plus, PerkinElmer) then exposed on radiographic films. Bands quantification was performed using ImageJ software (NIH, Bethesda, MA).

2.12. Data collection {#sec2.12}
---------------------

No statistical methods were used to predetermine sample sizes, but they are similar to those reported previously [@bib21]. In some experiments (PET analysis, leptin food intake studies and leptin effect on RQ), the same animals were also their own controls. In experiments with different treatment conditions (IHC following leptin or vehicle administration) mice were randomly assigned to the treatment.

2.13. Statistical analysis {#sec2.13}
--------------------------

All results are expressed as mean ± SEM. Data were analyzed using Statistica 9 software (StatSoft, USA). For multiple group designs, data were analyzed by two-way or repeated measure ANOVA followed by Fisher LSD post-hoc test. For designs with only two groups, statistical validity was assessed with unpaired *t* test or Mann--Whitney *U* test. *P* values less than 0.05 denote statistical significance.

3. Results {#sec3}
==========

3.1. Characterization of CB~1~ receptor expression in SF1-*CB*~*1*~-KO mice {#sec3.1}
---------------------------------------------------------------------------

SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO littermates were obtained as previously described in Ref. [@bib21]. FISH analysis revealed a specific strong decrease of CB~1~ receptor mRNA expression in the VMN of SF1-*CB*~*1*~-KO mice as compared to SF1-*CB*~*1*~-WT littermates ([Figure 1](#fig1){ref-type="fig"}A). Reduction in CB~1~ mRNA expression was present throughout the VMN, and particularly in the dorsomedial part of the nucleus, where leptin receptors are localized [@bib27]. Importantly, mRNA expression of the vesicular transporter of glutamate 2 receptor (vGlut2) did not differ between genotypes, excluding the possibility of a defective cytoarchitecture of the VMN in SF1-*CB*~*1*~-KO mice ([Figure 1](#fig1){ref-type="fig"}A). As expected [@bib16], no appreciable reduction of CB~1~ receptor mRNA was observed in other brain regions (data not shown).

SF1 is also present in the gonads, the adrenals and the pituitary [@bib12; @bib13], leaving open the possibility that Cre-mediated recombination of *CB*~*1*~ might have occurred in these organs. However, CB~1~ receptor mRNA expression was not altered in the testis, the adrenals or the pituitary of SF1-*CB*~*1*~-KO mice when compared with SF1-*CB*~*1*~-WT littermates ([Figure 1](#fig1){ref-type="fig"}B), suggesting that the expression of the CB~1~ receptor was preserved in these organs. Thus, SF1-*CB*~*1*~-KO mice carry a specific deletion of CB~1~ receptor in the VMN, thereby representing an ideal tool to study the roles of the endocannabinoid signaling in neurons located in this hypothalamic nucleus.

3.2. SF1-*CB*~*1*~-KO mice on standard chow are lean and have increased insulin sensitivity {#sec3.2}
-------------------------------------------------------------------------------------------

As measured from 7 until 15 weeks of age, *CB*~*1*~ deletion in SF1-positive neurons did not affect body weight in male mice maintained on a normocaloric, standard chow ([Figure 2](#fig2){ref-type="fig"}A). Even at younger age (4 weeks old), body weight was comparable between genotypes \[SF1-*CB*~*1*~-WT (*n* = 8): 11.6 ± 0.7 g vs. SF1-*CB*~*1*~-KO: 11.2 ± 0.7 g (*n* = 14), *P* = 0.68; *t*~(20)~ = 0.4093\]. However, body composition analysis carried out at 15 weeks of age revealed a significant decrease in fat mass in SF1-*CB*~*1*~-KO mice as compared with their WT littermates ([Figure 2](#fig2){ref-type="fig"}B), associated with a slight, non-significant increase in lean mass ([Figure 2](#fig2){ref-type="fig"}C). No differences were found in either cumulative food intake ([Figure 2](#fig2){ref-type="fig"}D) or weekly food intake during weeks 7--15 of age (SF1-*CB*~*1*~-WT: 5.2 ± 0.1 g vs. SF1-*CB*~*1*~-KO: 5.4 ± 0.1 g, *n* = 7, repeated measures ANOVA, genotype effect: *P* = 0.65; *F*~(1)~ = 0.214).

The amount of adiposity plays a role in glucose homeostasis and insulin sensitivity [@bib28]. Having found a decrease in fat mass in chow-fed SF1-*CB*~*1*~-KO mice, we studied glucose responses to glucose- or insulin-tolerance test (GTT or ITT, respectively). While fasting glucose levels were not different between genotypes ([Figure 2](#fig2){ref-type="fig"}E, values at time 0), SF1-*CB*~*1*~-KO mice had better glucose tolerance ([Figure 2](#fig2){ref-type="fig"}E,F) and increased insulin sensitivity ([Figure 2](#fig2){ref-type="fig"}G,H) as compared with their WT littermates.

Thus, in chow, deletion of CB~1~ receptors in VMN neurons decreases adiposity and improves glucose metabolism.

3.3. CB~1~ receptors in the VMN regulate SNS activity, lipid oxidation and WAT lipolysis under standard chow {#sec3.3}
------------------------------------------------------------------------------------------------------------

Since there were no obvious alterations in food intake that could explain the decreased adiposity of SF1-*CB*~*1*~-KO mice, we assessed whether this phenomenon could be due to changes in locomotor activity or in the use of energy substrates. Chow-fed SF1-*CB*~*1*~-KO and WT littermates had similar activity ([Figure 3](#fig3){ref-type="fig"}A) and VO~2~ consumption ([Figure 3](#fig3){ref-type="fig"}B) at 22 °C ambient temperature, but SF1-*CB*~*1*~-KO mice showed decreased respiratory quotient (RQ, [Figure 3](#fig3){ref-type="fig"}C), suggesting a higher consumption rate of lipids as energy source.

Activation of the SNS favors the oxidation of lipids rather than carbohydrates and induces lipolysis in the white adipose tissue (WAT) [@bib29; @bib30]. Several SNS functions are negatively affected by CB~1~ receptor signaling [@bib21; @bib31], whilst excitation of neurons of the VMN, particularly those located in the dorsomedial part of the nucleus, induces SNS activity [@bib15; @bib32]. To assess the impact of VMN CB~1~ receptors on SNS activity under chow, we physiologically and pharmacologically induced SNS activity, by exposing SF1-*CB*~*1*~-KO and their SF1-*CB*~*1*~-WT littermates to cold or by administering a β3-adrenergic receptor agonist, respectively. Changes in *in vivo* lipid oxidation and in the metabolic activity of the brown adipose tissue (BAT) were used as an indirect measure of SNS activity.

RQ differences between chow-fed SF1-*CB*~*1*~-KO and SF1-*CB*~*1*~-WT littermates were maintained when mice were exposed to 15 °C ambient temperature for 24 h and became particularly evident during the light phase of the diurnal cycle ([Figure 3](#fig3){ref-type="fig"}D). Additionally, positron emission tomography (PET) analysis showed that BAT ^18^F-FDG accumulation was greater in SF1-*CB*~*1*~-KO than in their SF1-*CB*~*1*~-WT littermates following short-term (4 h) exposure to 6 °C or the acute administration of the β3-adrenergic receptor agonist CL 316,223 ([Figure 3](#fig3){ref-type="fig"}E--G). These data thus strongly suggest that VMN CB~1~ receptors control SNS activity.

To then determine whether the enhanced SNS activity found in SF1-*CB*~*1*~-KO mice was associated with increased lipolysis, we studied the expression of the β3-adrenergic receptor and the activity of lipolytic markers in the epididymal WAT. As compared with SF1-*CB*~*1*~-WT littermates, SF1-*CB*~*1*~-KO mice had increased β3-adrenergic receptor protein expression in the WAT ([Figure 3](#fig3){ref-type="fig"}H,I). This was associated with increased phosphorylation of the lipolytic enzyme hormone-sensitive lipase (HSL) on ser 660 and 563 ([Figure 3](#fig3){ref-type="fig"}H,I), two phosphorylation sites induced by the activation of β3-adrenergic receptor in the WAT [@bib33]. Conversely, protein expression of the adipose triglyceride lipase (ATGL), another enzyme participating in lipolysis [@bib34], was similar between genotypes ([Figure 3](#fig3){ref-type="fig"}H,I).

3.4. CB~1~ receptors in the VMN determine the ability of leptin to decrease food intake and induce lipolysis in the WAT under standard chow {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------

A close relationship exists between leptin and CB~1~ receptor signaling in the regulation of energy balance [@bib5]. Knowing that SF1-positive neurons critically mediate the actions of leptin on metabolism [@bib16], we investigated the effects of the hormone in chow-fed SF1-*CB*~*1*~-KO and SF1-*CB*~*1*~-WT littermates.

Hypothalamic mRNA expression of the leptin receptor and of its downstream targets STAT3 and SOCS3 [@bib35] was similar between chow-fed SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice ([Supplementary Figure 1](#appsec2){ref-type="sec"}), and both genotypes responded to the dose of 5 mg/kg of leptin with a comparable 24 h decrease in food intake \[SF1-*CB*~*1*~-WT (*n* = 9): 25.2 ± 5.9% FI decrease vs. SF1-*CB*~*1*~-KO (*n* = 8): 25.5 ± 2.6% FI decrease, *P* = 0.96; *t*~(15)~ = 0.0474\]. However, the administration of a lower dose of the hormone (2.5 mg/kg) decreased 24 h food intake in SF1-*CB*~*1*~-KO mice only ([Figure 4](#fig4){ref-type="fig"}A) and led to a strong increase in STAT3 phosphorylation in the dorsomedial part of the VMN of SF1-*CB*~*1*~-KO but not SF1-*CB*~*1*~-WT mice ([Figure 4](#fig4){ref-type="fig"}B,C). Whilst no phospho-STAT3 labeling was found in the VMN of vehicle-treated mice ([Figure 4](#fig4){ref-type="fig"}B,C). Moreover, at metabolic level, leptin at 2.5 mg/kg rapidly increased *in vivo* lipid oxidation in SF1-*CB*~*1*~-KO but not in SF1-*CB*~*1*~-WT littermates ([Figure 4](#fig4){ref-type="fig"}D).

Leptin is known to activate neuronal circuits in the medio-basal hypothalamus leading to increased SNS outflow to the WAT [@bib36; @bib37] and to stimulate HSL in this tissue [@bib38]. Analysis of the expression of key lipolytic genes in the WAT of chow-fed SF1-*CB*~*1*~-KO and SF1-*CB*~*1*~-WT littermates after the administration of leptin at 2.5 mg/kg showed increased mRNA expression of the β~3~-adrenergic receptor, HSL, and ATGL in SF1-*CB*~*1*~-KO only ([Figure 4](#fig4){ref-type="fig"}E). Western blot studies confirmed that the acute administration of the hormone significantly increased protein expression of the β~3~-adrenergic receptor and induced HSL phosphorylation on ser 660 and 563 in the WAT of SF1-*CB*~*1*~-KO mice as compared with SF1-*CB*~*1*~-WT littermates ([Figure 4](#fig4){ref-type="fig"}F,G).

Overall, these findings imply that CB~1~ receptors in VMN neurons specifically modulate the sensitivity of the VMN to the action of leptin and determine leptin\'s ability to decrease food intake and to stimulate SNS activity and lipolysis in the WAT.

3.5. SF1-CB~1~-KO mice are obesity-prone when chronically exposed to an HFD {#sec3.5}
---------------------------------------------------------------------------

Deletion of the *CB*~*1*~ gene, either complete or limited to the principal forebrain neurons and SNS, protects from DIO [@bib31; @bib39]. SF1-positive neurons in the VMN play a role in the response to DIO [@bib16; @bib18; @bib40]. In particular, deletion of the leptin receptor in these neurons favors body weight gain during exposure to an HFD [@bib16]. To evaluate the specific role of CB~1~ receptors in the VMN in DIO, male SF1-*CB*~*1*~-KO and SF1-*CB*~*1*~-WT littermates were maintained for 8 weeks on a mild HFD (40% of calories from fat). Surprisingly, SF1-*CB*~*1*~-KO mice gained significantly more weight than their SF1-*CB*~*1*~-WT controls ([Figure 5](#fig5){ref-type="fig"}A), resulting in a significant increase in fat mass ([Figure 5](#fig5){ref-type="fig"}B), while lean mass was similar between genotypes ([Figure 5](#fig5){ref-type="fig"}C). To determine whether the increased adiposity had a detrimental effect on glucose metabolism, GTT and ITT were carried out. HFD-fed SF1-*CB*~*1*~-KO mice showed an overall worsened glucose tolerance in response to the acute administration of glucose during the GTT ([Figure 5](#fig5){ref-type="fig"}D), whilst no differences were observed between genotypes in the response to the ITT ([Figure 5](#fig5){ref-type="fig"}E). Thus, despite the mild lean phenotype of mutant mice under chow, SF1-*CB*~*1*~-KO mice are paradoxically more prone to the deleterious effects of an HFD.

3.6. SF1-CB~1~-KO mice are hyperphagic and have reduced lipid oxidation and lipolysis when chronically exposed to an HFD diet {#sec3.6}
-----------------------------------------------------------------------------------------------------------------------------

We then investigated the possible causes of the SF1-*CB*~*1*~-KO obese phenotype. HFD-fed SF1-*CB*~*1*~-KO mice had a significant increase in cumulative food intake as compared with HFD-fed SF1-*CB*~*1*~-WT littermates ([Figure 6](#fig6){ref-type="fig"}A). This increase was the result of a slight increase in daily food intake, present during both the dark and the light phase of the diurnal cycle (data not shown). We therefore went on to assess the mRNA expression levels of several hypothalamic neuropeptides involved in the regulation of food intake and found that only POMC mRNA expression was significantly decreased in the hypothalamus of obese SF1-*CB*~*1*~-KO mice ([Figure 6](#fig6){ref-type="fig"}B).

To further determine whether mechanisms other than the observed hyperphagia might have participated to the SF1-*CB*~*1*~-KO obese-prone phenotype, we studied changes in energy expenditure, locomotor activity and use of fuel substrates. No significant differences in feed efficiency or VO~2~ consumption were observed between obese SF1-*CB*~*1*~-KO mice and SF1-*CB*~*1*~-WT littermates ([Figure 6](#fig6){ref-type="fig"}C,D). In-cage activity was also similar between genotypes ([Figure 6](#fig6){ref-type="fig"}E). However, use of substrates was different, with HFD-fed SF1-*CB*~*1*~-KO mice having a significant decrease in lipid oxidation, as revealed by the increased RQ ([Figure 6](#fig6){ref-type="fig"}F), possibly favoring fat accumulation. Accordingly, SF1-*CB*~*1*~-KO mice had an almost 50% decrease in the mRNA expression of the β~3~-adrenergic receptor in the WAT as compared with control littermates ([Figure 6](#fig6){ref-type="fig"}G). Subsequent protein analysis confirmed the significant reduction in β~3~-adrenergic receptor in the WAT of HFD-fed SF1-*CB*~*1*~-KO mice only ([Figure 6](#fig6){ref-type="fig"}H,I), together with a decreased HSL phosphorylation at ser 660 and ser 563 ([Figure 6](#fig6){ref-type="fig"}H,I).

Thus, during chronic HFD exposure, lack of CB~1~ receptors in SF1-positive neurons leads to body weight gain and obesity by inducing hyperphagia and decreased use of lipid substrates, likely through decreased SNS outflow to the WAT.

3.7. SF1-*CB*~*1*~-KO mice develop impaired VMN leptin signaling when consuming an HFD {#sec3.7}
--------------------------------------------------------------------------------------

Resistance to the appetite-suppressant action of leptin and decreased hypothalamic leptin signaling are features commonly associated with DIO. However, once obesity is established it is difficult to determine whether hypothalamic alterations in leptin signaling are the cause or the consequence of the increased adiposity [@bib41]. To determine whether decreased leptin signaling might have a causal role in the SF1-*CB*~*1*~-KO obese-prone phenotype described during chronic HFD exposure, we investigated leptin-induced STAT3 phosphorylation in the VMN of SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for only 2 weeks before the acute administration of leptin (5 mg/kg). Animals were matched by body weight (SF1-*CB*~*1*~-WT, 29.1 ± 1 g vs. SF1-*CB*~*1*~-KO, 28.8 ± 2.1 g, *n* = 4; *P* = 0.90, *t*~(6)~ = 0.1279) and by body composition (fat mass: SF1-*CB*~*1*~-WT, 5.1 ± 0.5 g vs. SF1-*CB*~*1*~-KO, 5.5 ± 0.8 g; *P* = 0.68, *t*~(6)~ = 0.4267; lean mass: SF1-*CB*~*1*~-WT, 23.8 ± 0.7 g vs. SF1-*CB*~*1*~-KO, 23.2 ± 1.2 g, *n* = 4; *P* = 0.65, *t*~(6)~ = 0.4636) in order to study the action of leptin in the absence of any possible confounding effect due to differences in adiposity. Under these conditions, SF1-*CB*~*1*~-KO mice displayed a significantly decreased leptin-induced phospho-STAT3 response in the VMN as compared with SF1-*CB*~*1*~-WT littermates ([Figure 7](#fig7){ref-type="fig"}A,B). Thus, exposure to HFD blunts molecular leptin sensitivity in the VMN of SF1-*CB*~*1*~-KO before they overtly gain weight.

4. Discussion {#sec4}
=============

What we eat critically influences the biological mechanisms regulating energy balance. Besides obviously providing different amounts of energy, diets with different nutrient composition affect a plethora of metabolic responses, and specific nutrients can work as signals able to modulate well-identified intracellular pathways [@bib3; @bib4]. However, less is known about how diet-induced metabolic changes are integrated and coordinated at the CNS level.

The present study demonstrates the critical role of CB~1~ receptors in the VMN in regulating metabolic flexibility and in determining behavioral and metabolic responses to leptin.

During consumption of a standard chow, lack of *CB*~*1*~ in SF1-positive neurons heightens SNS outflow and lipolysis, thus decreasing adiposity, while improving glucose tolerance and insulin sensitivity. Conversely, during exposure to an HFD, deletion of the *CB*~*1*~ gene from the VMN blunts peripheral use of lipid substrates and causes hyperphagia, body weight gain and glucose intolerance. Importantly, the diet-dependent, bidirectional regulation of energy balance observed when *CB*~*1*~ is deleted from VMN neurons is closely intertwined with the effects of leptin. Thus, an enhanced sensitivity to the anorectic and metabolic action of the hormone is observed in mutant mice under chow, whereas lack of *CB*~*1*~ in the VMN of animals fed with an HFD for only 2 weeks determines the appearance of molecular leptin resistance in the VMN.

When exposed to a diet with a prevalent carbohydrate content, such as the regular chow routinely used in animal studies, SF1-*CB*~*1*~-KO mice did not show changes in body weight or food intake, but had a small, significant decrease in fat mass. This was associated with improved peripheral glucose metabolism and resulted from enhanced SNS activity, leading to increased metabolism in the BAT, lipolysis in the WAT and *in vivo* lipid oxidation. Overall, these findings demonstrate that CB~1~ receptors in the VMN affect peripheral metabolic responses by modulating VMN-SNS outflow.

Studies in the '80s had initially proposed that VMN neurons exert their metabolic functions on the periphery by modulating the activity of the SNS [@bib42; @bib43]. For instance, VMN lesions reduce SNS outflow in a number of tissues, including the WAT and the BAT [@bib42; @bib43]. Conversely, administration of leptin directly into the VMN produces elevations of plasma epinephrine and norepinephrine [@bib44]. However, although evidence has clearly suggested that excitation of VMN neurons evokes SNS outflow, the anatomical and mechanistic bases underlying VMN-mediated autonomic functions have remained for a long time unclear. Only very recent studies have finally demonstrated the neuroanatomical connection between the VMN and the SNS. In particular, it has been shown that SF1-positive neurons of the dorsomedial subdivision of the VMN project to autonomic centers of both the hypothalamus and hindbrain [@bib15]. Taking into account that SF1-positive neurons are largely glutamatergic and that CB~1~ receptor agonists inhibit the firing of action potentials of SF1-positive neurons [@bib20], deletion of *CB*~*1*~ on this neuronal population is expected to facilitate SF1-positive neurons activation and to increase SNS activity. Our *in vivo* and *ex-vivo* findings fully support this conclusion.

The relationship between leptin and hypothalamic endocannabinoid signaling was established more than a decade ago [@bib45], but the functional consequences of this interaction have been only partially addressed [@bib22; @bib46; @bib47]. SF1-positive neurons express leptin receptors [@bib27] and are the target of the action of leptin [@bib16]. Our data now demonstrate that leptin\'s ability to regulate food intake and peripheral lipid metabolism depend upon CB~1~ receptors expressed on SF1-positive neurons. In particular leptin engages, under the modulatory control of endocannabinoid signaling, the above-mentioned VMN-SNS output to exert its metabolic actions. In 2008, Buettner and colleagues demonstrated that direct administration of leptin in the rat medio-basal hypothalamus stimulated WAT lipolysis by increasing SNS outflow [@bib36]. However, that study did not provide any information about the exact neuronal population or the cellular signaling pathways involved in determining the effects of leptin on the WAT. Our present findings reveal that such population is the SF1-positive neurons, which regulate SNS outflow *via* endocannabinoid signaling.

Our data also reveal that lack of *CB*~*1*~ in SF1-positive neurons facilitates molecular leptin sensitivity specifically within the VMN, as assessed by leptin-induced phospho-STAT3 expression, the gold standard method used to study hypothalamic leptin signaling [@bib41]. This finding could be explained by taking into account that SF1-positive neurons form a local circuit with extensive axonal fibers and terminals particularly in the dorsomedial part of the VMN [@bib15]. Thus, this local circuit is the likely anatomical substrate used by the endocannabinoid signaling to fine-tune VMN responses to leptin.

As opposed to what was observed in chow, when SF1-*CB*~*1*~-KO mice were chronically exposed to a mild HFD, they gained more weight and fat mass than their WT littermates. This was due to the presence of hyperphagia, likely due to decreased hypothalamic expression of POMC. This molecular change is of interest, particularly considering that VMN neurons provide excitatory input to POMC neurons in the ARC, thus facilitating the activation of this anorexigenic neuronal pathway [@bib48].

Moreover, obese SF1-*CB*~*1*~-KO mice showed decreased *in vivo* lipid oxidation and lipolysis in the WAT. These metabolic changes were related to reduced SNS outflow, as suggested by the decreased activity of SNS-dependent lipolytic markers and β~3~-adrenergic receptor expression in the WAT. Interestingly, long-term (over 10 years) changes in body weight in humans are inversely correlated with β~3~-adrenergic receptor induced lipolysis in white adipocytes, so that subjects with low basal β~3~-adrenergic receptor function gain weight, while those with high β~3~-adrenergic receptor function are protected from weight gain, implying a critical role for adipocyte β~3~-adrenergic receptor activity in body weight regulation [@bib49].

Leptin receptor signaling, as assessed by STAT3 phosphorylation, was impaired in the VMN of SF1-*CB*~*1*~-KO mice consuming an HFD, even before the occurrence of changes in body weight and adiposity, thus suggesting that CB~1~ receptors on VMN neurons may actually protect from the development of HFD-induced leptin resistance. Moreover, in view of the link among central leptin action, modulation of SNS outflow and WAT lipolysis [@bib36], the present findings hint that decreased WAT β~3~-adrenergic receptor expression and activity found in obese SF1-*CB*~*1*~-KO mice might be the result of the decreased leptin signaling described in the VMN of HFD-fed SF1-*CB*~*1*~-KO mice before they phenotypically differ from HFD-fed SF1-*CB*~*1*~-WT.

The molecular, behavioral and metabolic changes found in SF1-*CB*~*1*~-KO mice on HFD, are likely the result of blunted activity of VMN neurons projecting to autonomic centers regulating the SNS, to the ARC and to the VMN itself. Thus, while in chow endocannabinoid signaling on VMN neurons favors body weight gain, in HFD it protects from DIO. The reason for this opposite, diet-dependent effect may reside in the ability of nutrients to directly affect both VMN neurons activity and endocannabinoid signaling. Indeed, VMN neurons use both glucose and long-chain fatty acids as signaling molecules to alter their activity [@bib50], whilst endocannabinoid-mediated neuronal function and plasticity are affected by dietary fat content [@bib8].

Lastly, future studies will have to clarify the molecular cascade downstream the CB~1~ receptor. Recent evidence suggests that modulation of the cellular fuel sensor AMP-activated protein kinase (AMPK) directly in the VMN regulates SNS outflow and BAT function [@bib51]. Cannabinoids stimulate AMPK activity in the hypothalamus [@bib52]. Thus, AMPK may be a likely downstream target of CB~1~ receptors in VMN neurons.

Taken together, these data demonstrate that CB~1~ receptors in the VMN determine metabolic and molecular adaptations to different environmental dietary conditions. In order to do so, CB~1~ receptors in VMN neurons orchestrate peripheral use of substrates and fine-tune sensitivity (or resistance) to the actions of leptin.
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![Characterization of CB~1~ receptor mRNA expression in SF1-*CB*~*1*~-KO mice. (A) Representative images taken at the level of the ventromedial nucleus of the hypothalamus from fluorescent *in situ* hybridization studies showing the marker of glutamatergic neurons vesicular glutamate transporter 2 (vGlut2, red) and CB~1~ receptor (green) mRNA expression in SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice (*n* = 3--4 per genotype). Nuclear counter stain carried out with DAPI. V: third ventricle. Scale bar: 400 μm. (B) CB~1~ receptor mRNA expression evaluated by qPCR in the adrenals, testis and pituitary of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO littermates (*n* = 5). Data are represented as mean ± SEM.](gr1){#fig1}

![Lack of CB~1~ receptors in SF1-positive neurons leads to leanness and improved glucose metabolism under standard chow. (A) Weekly body weight gain, (B) fat mass, (C) lean mass and (D) cumulative food intake in chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO littermates (*n* = 7). (E) Glucose tolerance test, (G) insulin tolerance test and (F, H) related area under the curve (AUC) carried out in chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice (*n* = 7--9). Data are represented as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.01; ^\#^*P* \< 0.05 genotype effect.](gr2){#fig2}

![CB~1~ receptors in SF1-positive neurons regulate SNS activity, lipid oxidation and WAT lipolysis. (A) In-cage locomotor activity, (B) VO~2~ consumption and (C) respiratory quotient (RQ) during the dark and light phases determined in 15-weeks old chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice at 22 °C ambient temperature (*n* = 5--6). (d) RQ during the dark and light phases assessed in 15-weeks old chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice at 15 °C ambient temperature (*n* = 6). (E) Representative sagittal (main figure) and transverse (smaller insets) PET images showing ^18^F-FDG accumulation expressed as standard absorption values (SUV) in the BAT of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice. Red lines indicate the image sections reported in the transverse views; images were from the study with the β3R agonist CL 316,243. SUV quantification after (F) 4 h exposure to 6 °C or (G) treatment with β3R agonist of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice expressed as % of basal non-stimulated condition in the same animals (*n* = 6). (H) Representative western blot scans and (I) quantification of β3R, phospho-HSL ser 660, phospho-HSL ser 563, HSL and ATGL protein expression in the WAT of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained at 22 °C (*n* = 6--11; β-actin: loading control). Data are represented as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01 genotype effect.](gr3){#fig3}

![Leptin actions on food intake and WAT lipolysis depend upon CB~1~ receptors in SF1-positive neurons. (A) 24 h food intake of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice treated with leptin (2.5 mg/kg) or vehicle (*n* = 5--7). (B) Representative staining for phospho-STAT3 (dark brown nuclear dots) in the VMN (dotted line) of chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice treated with leptin (2.5 mg/kg) or vehicle and (C) related quantification in the VMN (*n* = 4). Scale bar in (A): 50 μm. (D) 1 h RQ changes recorded during the light phase in chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice in response to leptin (2.5 mg/kg) (*n* = 5). Data are expressed as % of change vs. vehicle administration carried out in the same animals the day before. (E) mRNA expression levels of β3R, HSL and ATGL assessed 30 min after leptin administration (2.5 mg/kg) in chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice (*n* = 5--6). (F) Representative western blot scans and (G) quantification of β3R, phospho-HSL ser 660, phospho-HSL ser 563, HSL and ATGL protein expression in the WAT of leptin-treated (2.5 mg/kg) chow-fed male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice (*n* = 6--7; β-actin: loading control). Data are represented as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.01, \*\*\**P* \< 0.001.](gr4){#fig4}

![SF1-*CB*~*1*~-KO mice are obesity-prone when chronically exposed to a mild HFD. (A) Weekly body weight gain, (B) fat mass and (C) lean mass in male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO littermates maintained on HFD for 8 weeks (*n* = 6--10). (D) Glucose tolerance test and (E) insulin tolerance test carried out in male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 10--14). Data are represented as mean ± SEM. \**P* \< 0.05; ^\#^*P* \< 0.05 genotype effect.](gr5){#fig5}

![SF1-*CB*~*1*~-KO mice are hyperphagic and have reduced lipid oxidation and lipolysis when chronically exposed to HFD. (A) Cumulative food intake of male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 6--10). (B) mRNA expression levels of BDNF, CRH, AgRP, NPY and POMC in the hypothalamus of male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 5--9). (C) Feed efficiency expressed as body weight gain over caloric intake × 100 in male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 6--10). (D) VO~2~ consumption, (E) in-cage locomotor activity and (F) RQ during the dark and light phases determined at 22 °C ambient temperature in 15-weeks old male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 7--12). (G) mRNA expression levels of β3R, HSL and ATGL in the WAT of male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 6). (H) Representative western blot scans and (I) quantification of β3R, phospho-HSL ser 660, phospho-HSL ser 563, HSL and ATGL protein expression in the WAT of male WT and SF1-*CB*~*1*~-KO mice maintained on HFD for 8 weeks (*n* = 7--10; β-actin: loading control). Data are represented as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.01; ^\#^*P* \< 0.05 genotype effect.](gr6){#fig6}

![SF1-*CB*~*1*~-KO mice have impaired VMN leptin signaling in response to HFD consumption. (A) Representative staining for phospho-STAT3 (dark brown nuclear dots) in the VMN (dotted line) of male SF1-*CB*~*1*~-WT and SF1-*CB*~*1*~-KO mice fed with HFD for 2 weeks and then treated with leptin (5 mg/kg) or its vehicle; (B) quantification of phospho-STAT3 staining in the VMN (*n* = 4). Scale bar in (A): 50 μm. Data are represented as mean ± SEM. \**P* \< 0.05.](gr7){#fig7}
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